短效胰岛素类似物的研究进展  

Recent progress in rapid-acting insulin analogues

作　　者：曹宇铭[1] 朱铁虹[1] 

机构地区：[1]天津医科大学总医院内分泌科,300052

出　　处：《国际内分泌代谢杂志》2006年第2期87-89,共3页International Journal of Endocrinology and Metabolism

摘　　要：短效胰岛素类似物如Lispro和Aspart,能模似胰岛素的生理性分泌,适于餐时即时注射并能根据具体进食量于餐后及时调整用量,故更能有效控制餐后高血糖,降低并发症风险。因减少了饮食的限制,提高了饮食和空闲时间安排的灵活性,同时低血糖风险小,从而显著改善了患者的生活质量;同时只需持续皮下注射即可纠正酮症酸中毒,降低了治疗门槛,节约了开支。由于其结构的改变,还可以使患者自身的胰岛素分泌增加。因此,短效胰岛素可能在控制血糖达标,减少糖尿病的并发症方面发挥重要作用。The rapid-acting insulin analogues, such as Lispro and Aspact, can mimic the physiological secretion of insulin, which making it suitable for injection during meal. Further more, the dose can be adjusted according to the actual calories and carbohydrates ingested. So it can significantly reduce the postprandial hyperglycemia and decrease the risks of complications. The rapid-acting insulin analogues can improve patients＇ living qualitis due to decrease diet restriction.q, increased dietary and leisure time flexibility, and reduced risk of hypoglycemia. Subcutaneous injection of the rapid-acting insulin analogue alone can correct diabetic ketoaeidosis, leading to decreased of treatment threshold and saving the treatment cost. Because of the change of its molecular structure, the patients＇ endogenous insulin secretion also can be increased. Therefore, the rapid-acting insulin analogues may play important roles in controlling the blood sugar to target level and decreasing the prevalence of diabetic complications.

关 键 词：胰岛素类似物 LISPRO ASPART 糖尿病 

分 类 号：R587.1[医药卫生—内分泌]